Clinical Trials

Fresh off a $260M IPO, Seaport Therapeutics is advancing a de-risked pipeline for depression and anxiety, leveraging its novel platform to unlock new potential.

With blockbuster sales for its MS drug BRIUMVI, TG Therapeutics is raising revenue targets and aggressively expanding its pipeline into new diseases.

A new partnership aims to treat PTSD with psilocybin, revealing a broader strategy to navigate regulatory mazes and build the clinical infrastructure for a new era of medicine.

With cash dwindling and a pivotal trial result looming after a recent failure, Vistagen brings a seasoned drug developer aboard to navigate the turbulence.

With Phase 3 results for Levosimendan imminent and its cash runway secured, Tenax Therapeutics faces a make-or-break moment in the PH-HFpEF space.

Karyopharm plans an accelerated FDA filing for its selinexor combo in myelofibrosis. The move hinges on a key surrogate endpoint and a race against competitors.

Karyopharm's stock plummets after a key cancer trial fails, forcing a strategic retreat and a hard pivot toward more promising assets in its pipeline.

With $217M in the bank, SAB Biotherapeutics has silenced liquidity fears. Now, all eyes are on its novel T1D drug and the unproven promise of its cow-powered tech.

As Cellectar Biosciences preps its Q2 report, all eyes are on its cash runway and the immense promise of its targeted cancer therapy platform.

Clinical research leader Novotech offers a strategic roadmap for biotech and pharma, aiming to de-risk and accelerate the complex world of autoimmune drug development.

With a lens clinically shown to stop nearsightedness in 9 of 10 kids, HOYA isn't just launching a product; it's making a power play in a blurry market.

With myopia rates soaring, HOYA's MiYOSMART iQ lens enters Canada with unprecedented clinical results, signaling a major strategic shift in pediatric vision care.

Regeneron's Q2 results reveal soaring sales from Dupixent and EYLEA HD, a pivotal pipeline, and a major financial reset with Sanofi. What's next?

With FDA clearance for IKS04, Iksuda Therapeutics unveils a novel co-dosing strategy to deliver a potent payload past notorious tumor barriers.

Lōkahi Therapeutics aims to turn 15 injections into one for its pain drug LT-100, a move that could transform patient care and unlock major commercial value.

Latigo Biotherapeutics' new drug LTG-001 shows superior, faster pain relief than Vicodin in a major trial, offering a potent new tool against the opioid crisis.

As RenovoRx preps its Q2 update, it's proving its mettle on two fronts: impressive sales of its RenovoCath device and a critical milestone in its pancreatic cancer trial.

Clene Inc. heads to the Canaccord Growth Conference with promising ALS data and a clear regulatory path, but faces a critical test of investor confidence.

As Akebia Therapeutics preps its Q2 report, all eyes are on Vafseo's uptake, a declining Auryxia, and a costly R&D push into rare kidney diseases.

With a novel drug targeting an unaddressed cause of glaucoma, Qlaris Bio adds a seasoned expert to its board, signaling a pivotal push toward market entry.